Crescita Therapeutics Inc. (CRRTF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Crescita Therapeutics Inc. (CRRTF) with AI Score 50/100 (Hold). Crescita Therapeutics Inc. is a Canadian dermatology company focused on developing and commercializing prescription and non-prescription skincare products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Crescita Therapeutics Inc. (CRRTF) Healthcare & Pipeline Overview
Crescita Therapeutics Inc. is a dermatology company focused on prescription and non-prescription skincare products, operating through commercial skincare, licensing, and manufacturing segments. With proprietary technologies like MMPE and DuraPeel, Crescita develops topicals, including cannabis-based products, and markets brands like Laboratoire Dr Renaud and Pro-Derm, primarily in Canada, the US, and Asia.
Investment Thesis
Crescita Therapeutics operates in the growing dermatology market with a focus on both prescription and non-prescription skincare products. The company's proprietary technologies, such as MMPE and DuraPeel, offer a competitive advantage in developing topical treatments. With a market capitalization of $0.01 billion and a P/E ratio of 30.09, Crescita's profitability, indicated by a 2.1% profit margin and a 51.8% gross margin, suggests potential for growth. Key growth catalysts include the advancement of its pipeline products, such as CTX-101 in Phase III trials, and expansion of its commercial skincare segment. However, investors should be aware of potential risks associated with regulatory approvals and competition in the dermatology market. The company's beta of 0.29 indicates lower volatility compared to the market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.01 billion indicates a small-cap company with potential for growth.
- P/E Ratio of 30.09 suggests the company is trading at a premium compared to its earnings.
- Profit Margin of 2.1% indicates room for improvement in operational efficiency and profitability.
- Gross Margin of 51.8% demonstrates the company's ability to manage production costs effectively.
- Beta of 0.29 suggests the stock is less volatile than the market, potentially offering stability to investors.
Competitors & Peers
Strengths
- Proprietary platform technologies (MMPE and DuraPeel).
- Diverse product portfolio of prescription and non-prescription skincare products.
- Established brands with customer recognition.
- Strategic partnerships with companies like Sundial Growers Inc. and Taro Pharmaceuticals Inc.
Weaknesses
- Small market capitalization, making it vulnerable to market fluctuations.
- Low profit margin of 2.1% indicates potential operational inefficiencies.
- Reliance on licensing agreements for revenue generation.
- Limited geographic presence compared to larger competitors.
Catalysts
- Upcoming: Results from Phase III clinical trials for CTX-101, a topical formulation for plaque psoriasis, expected by Q4 2026.
- Ongoing: Expansion of the commercial skincare segment through new product launches and increased distribution.
- Ongoing: Development and commercialization of cannabis-based topicals through the agreement with Sundial Growers Inc.
- Ongoing: New licensing and royalty agreements leveraging proprietary technologies.
Risks
- Potential: Regulatory hurdles and delays in obtaining approvals for prescription drugs.
- Potential: Intense competition from established players in the dermatology market.
- Potential: Economic downturns affecting consumer spending on skincare products.
- Potential: Product recalls or liability claims related to skincare products.
- Ongoing: Limited liquidity and price volatility due to trading on the OTC market.
Growth Opportunities
- Expansion of Commercial Skincare Segment: Crescita can expand its commercial skincare segment by introducing new products and expanding its distribution network. The global skincare market is projected to reach $183.03 billion by 2028, offering significant growth potential. Timeline: Ongoing, with continuous product development and market expansion efforts.
- Advancement of CTX-101 Clinical Trials: The successful completion of Phase III clinical trials for CTX-101, a topical formulation for plaque psoriasis, represents a significant growth opportunity. Positive trial results could lead to regulatory approval and commercialization, addressing a substantial market need. Timeline: Upcoming, pending trial results and regulatory review.
- Licensing and Royalty Agreements: Crescita can leverage its proprietary technologies, such as MMPE and DuraPeel, to enter into new licensing and royalty agreements with other companies. This strategy can generate revenue and expand the company's market reach without significant capital investment. Timeline: Ongoing, with continuous efforts to identify and secure new partnerships.
- Development of Cannabis-Based Topicals: Crescita's development and licensing agreement with Sundial Growers Inc. to develop cannabis-based topicals presents a unique growth opportunity. The market for cannabis-infused skincare products is growing, driven by increasing consumer interest in natural and alternative treatments. Timeline: Ongoing, with product development and regulatory considerations.
- Geographic Expansion: Crescita can expand its geographic footprint beyond Canada and the United States, targeting new markets in Asia and Europe. The global skincare market is diverse, with varying consumer preferences and market dynamics. Adapting its product portfolio to meet local needs can drive growth. Timeline: Ongoing, with market research and strategic planning.
Opportunities
- Expansion into new geographic markets, particularly in Asia and Europe.
- Further development and commercialization of cannabis-based topicals.
- Advancement of pipeline products, such as CTX-101, through clinical trials.
- Increased demand for skincare products driven by an aging population.
Threats
- Intense competition from established players in the dermatology market.
- Regulatory hurdles and approval processes for prescription drugs.
- Economic downturns affecting consumer spending on skincare products.
- Potential for product recalls or liability claims.
Competitive Advantages
- Proprietary Technologies: MMPE and DuraPeel technologies provide a competitive advantage in developing topical treatments.
- Established Brands: Brands like Laboratoire Dr Renaud and Pro-Derm have a strong reputation and customer loyalty.
- Strategic Partnerships: Agreements with companies like Sundial Growers Inc. and Taro Pharmaceuticals Inc. enhance product development and market reach.
- Diverse Product Portfolio: A range of prescription and non-prescription products caters to various skincare needs.
About CRRTF
Crescita Therapeutics Inc., incorporated in 2016 and headquartered in Laval, Canada, is a dermatology company engaged in the development, manufacturing, and commercialization of a range of skincare products. The company operates through three key segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. Crescita's foundation lies in its proprietary platform technologies, including MMPE (Multi-Molecular Penetration Enhancer) and DuraPeel, which facilitate the development of topical treatments, including those containing cannabis and hemp derivatives. Crescita's product portfolio includes both prescription and non-prescription skincare solutions. Its prescription offerings feature Pliaglis, a topical anesthetic cream used prior to dermatological procedures, and pipeline products like CTX-101, a Phase III topical formulation for plaque psoriasis, and CTX-102, a Phase I topical formulation targeting an undisclosed dermatological condition. The company's non-prescription skincare products are marketed under brands such as Laboratoire Dr Renaud, Pro-Derm, Alyria, and Dermazulene, targeting various skin concerns, including aging, acne, rosacea, and sensitivity. Crescita also offers NCTF 135 HA, a skin revitalization solution. Crescita has established strategic partnerships, including a development and licensing agreement with Sundial Growers Inc. for cannabis-based products, a commercialization license agreement with Cantabria Labs Inc., and a development and commercialization license agreement with Taro Pharmaceuticals Inc. These collaborations enhance Crescita's product development and market reach, solidifying its position in the dermatology market.
What They Do
- Develops and commercializes prescription and non-prescription skincare products.
- Operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services.
- Owns proprietary platform technologies, including MMPE and DuraPeel.
- Offers prescription products like Pliaglis and pipeline products like CTX-101 and CTX-102.
- Markets non-prescription skincare products under brands such as Laboratoire Dr Renaud and Pro-Derm.
- Engages in development and licensing agreements with companies like Sundial Growers Inc. and Taro Pharmaceuticals Inc.
Business Model
- Develops and manufactures skincare products, both prescription and non-prescription.
- Generates revenue through sales of its commercial skincare products.
- Earns royalties and licensing fees from partnerships and agreements.
- Provides manufacturing and services to other companies in the dermatology space.
Industry Context
Crescita Therapeutics operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. The dermatology market is characterized by increasing demand for both prescription and non-prescription skincare products, driven by an aging population and growing awareness of skincare. The competitive landscape includes established players and emerging companies focused on innovative treatments and formulations. Crescita's proprietary technologies and diverse product portfolio position it to capitalize on market trends, though it faces competition from companies like AYRWF (Ayr Wellness Inc.) and CLCFF (Clene Nanomedicine Inc.).
Key Customers
- Consumers seeking skincare solutions for aging, acne, rosacea, pigmentation, dehydration, and sensitivity.
- Dermatologists and medical professionals who use and recommend Crescita's prescription products.
- Licensing partners who utilize Crescita's technologies and formulations.
- Asian consumers interested in skincare products under the Dermazulene brand.
Financials
Chart & Info
Crescita Therapeutics Inc. (CRRTF) stock price: Price data unavailable
Latest News
-
Crescita Therapeutics Up More Than 50% On Offer From ClinActive Holdings
Yahoo! Finance: CRRTF News · Mar 16, 2026
-
Crescita Announces Definitive Agreement to Be Acquired by ClinActiv Holdings in an All-Cash Transaction at a Significant Premium
businesswire.com · Mar 16, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CRRTF.
Price Targets
Wall Street price target analysis for CRRTF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CRRTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Serge Verreault
CEO
Serge Verreault serves as the CEO of Crescita Therapeutics Inc. His background encompasses extensive experience in the pharmaceutical and healthcare industries. Prior to joining Crescita, Verreault held various leadership positions at pharmaceutical companies, focusing on strategic planning, business development, and commercial operations. He has a proven track record of driving growth and innovation in the healthcare sector. His expertise includes product development, market access, and sales management.
Track Record: Under Serge Verreault's leadership, Crescita Therapeutics has focused on expanding its product portfolio and strengthening its market presence. Key achievements include advancing the clinical development of CTX-101 and expanding licensing agreements. Verreault has also overseen the growth of the company's commercial skincare segment, driving revenue growth and profitability. His strategic decisions have positioned Crescita as a key player in the dermatology market.
CRRTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Crescita Therapeutics Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited regulatory oversight and may not provide regular financial disclosures, increasing the risk for investors compared to companies listed on major exchanges like the NYSE or NASDAQ. OTC Other stocks are typically more speculative and require greater due diligence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Liquidity: Low trading volume can make it difficult to buy or sell shares without affecting the price.
- Lack of Transparency: Inconsistent or limited financial disclosures increase the risk of investing in CRRTF.
- Regulatory Oversight: Reduced regulatory oversight on the OTC Other tier may expose investors to greater risk.
- Price Volatility: OTC stocks are often more volatile than those listed on major exchanges.
- Information Availability: Difficulty in obtaining reliable and timely information about the company.
- Verify the company's financial disclosures and reporting practices.
- Assess the trading volume and bid-ask spread to understand liquidity.
- Research the company's management team and their track record.
- Review the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Consult with a financial advisor to assess the risks and potential rewards.
- Understand the OTC market and the specific risks associated with OTC Other stocks.
- Established Brands: The company's established brands, such as Laboratoire Dr Renaud and Pro-Derm, indicate a history of operations.
- Proprietary Technologies: Ownership of proprietary technologies like MMPE and DuraPeel suggests innovation and differentiation.
- Strategic Partnerships: Agreements with companies like Sundial Growers Inc. and Taro Pharmaceuticals Inc. demonstrate industry recognition.
- CEO Leadership: Serge Verreault's experience in the pharmaceutical industry adds credibility to the company's management.
Crescita Therapeutics Inc. Stock: Key Questions Answered
What does Crescita Therapeutics Inc. do?
Crescita Therapeutics Inc. is a dermatology company that develops, manufactures, and commercializes prescription and non-prescription skincare products. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. Its product portfolio includes prescription treatments like Pliaglis and pipeline products such as CTX-101 for plaque psoriasis, as well as non-prescription skincare products marketed under brands like Laboratoire Dr Renaud and Pro-Derm. Crescita also engages in licensing agreements to leverage its proprietary technologies.
What do analysts say about CRRTF stock?
As of 2026-03-16, formal analyst ratings for CRRTF are not widely available due to its OTC listing and smaller market capitalization. Investors should conduct their own due diligence and consider factors such as the company's pipeline progress, revenue growth in its commercial skincare segment, and the potential of its licensing agreements. Valuation metrics should be interpreted cautiously, considering the company's size and OTC market dynamics. Further AI analysis is pending.
What are the main risks for CRRTF?
The main risks for Crescita Therapeutics Inc. include regulatory hurdles in obtaining approvals for its prescription drugs, intense competition in the dermatology market, and potential economic downturns affecting consumer spending. Additionally, the company faces risks associated with product recalls, liability claims, and the inherent volatility of trading on the OTC market. Limited liquidity and transparency on the OTC Other tier also pose significant risks for investors.
What are the key factors to evaluate for CRRTF?
Crescita Therapeutics Inc. (CRRTF) currently holds an AI score of 50/100, indicating moderate score. Key strength: Proprietary platform technologies (MMPE and DuraPeel).. Primary risk to monitor: Potential: Regulatory hurdles and delays in obtaining approvals for prescription drugs.. This is not financial advice.
How frequently does CRRTF data refresh on this page?
CRRTF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CRRTF's recent stock price performance?
Recent price movement in Crescita Therapeutics Inc. (CRRTF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary platform technologies (MMPE and DuraPeel).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CRRTF overvalued or undervalued right now?
Determining whether Crescita Therapeutics Inc. (CRRTF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CRRTF?
Before investing in Crescita Therapeutics Inc. (CRRTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- OTC market data may be limited and less reliable than data from major exchanges.
- AI analysis is pending and may provide additional insights.